Jianmin Pharmaceutical Group Co Ltd Asset Resilience Ratio
Jianmin Pharmaceutical Group Co Ltd asset resilience ratio. Jianmin Pharmaceutical Group Co Ltd (600976) has an Asset Resilience Ratio of 20.61% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 600976 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jianmin Pharmaceutical Group Co Ltd (2001–2025)
Asset resilience ratio of Jianmin Pharmaceutical Group Co Ltd from 2001 to 2025. This chart shows how Jianmin Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Jianmin Pharmaceutical Group Co Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jianmin Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 600976 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥966.27 Million | 20.61% |
| Total Liquid Assets | CN¥966.27 Million | 20.61% |
Asset Resilience Insights
- Good Liquidity Position: Jianmin Pharmaceutical Group Co Ltd maintains a healthy 20.61% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Jianmin Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jianmin Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Jianmin Pharmaceutical Group Co Ltd Asset Resilience Ratio by Year (2001–2025)
Jianmin Pharmaceutical Group Co Ltd asset resilience ratio by year from 2001 to 2025. The table below shows the annual Asset Resilience Ratio data for Jianmin Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.09% | CN¥1.09 Billion ≈ $159.60 Million |
CN¥4.53 Billion ≈ $662.43 Million |
+1.79pp |
| 2024-12-31 | 22.31% | CN¥954.19 Million ≈ $139.63 Million |
CN¥4.28 Billion ≈ $625.95 Million |
+5.64pp |
| 2023-12-31 | 16.66% | CN¥694.46 Million ≈ $101.62 Million |
CN¥4.17 Billion ≈ $609.90 Million |
-2.00pp |
| 2022-12-31 | 18.66% | CN¥641.38 Million ≈ $93.85 Million |
CN¥3.44 Billion ≈ $503.04 Million |
-0.41pp |
| 2021-12-31 | 19.06% | CN¥538.63 Million ≈ $78.82 Million |
CN¥2.83 Billion ≈ $413.47 Million |
-1.04pp |
| 2020-12-31 | 20.10% | CN¥485.79 Million ≈ $71.09 Million |
CN¥2.42 Billion ≈ $353.71 Million |
+2.87pp |
| 2019-12-31 | 17.22% | CN¥332.17 Million ≈ $48.61 Million |
CN¥1.93 Billion ≈ $282.21 Million |
-4.70pp |
| 2018-12-31 | 21.93% | CN¥377.60 Million ≈ $55.25 Million |
CN¥1.72 Billion ≈ $252.01 Million |
+18.60pp |
| 2017-12-31 | 3.33% | CN¥64.00 Million ≈ $9.36 Million |
CN¥1.92 Billion ≈ $281.56 Million |
-8.57pp |
| 2016-12-31 | 11.89% | CN¥215.00 Million ≈ $31.46 Million |
CN¥1.81 Billion ≈ $264.54 Million |
-10.28pp |
| 2015-12-31 | 22.17% | CN¥355.25 Million ≈ $51.98 Million |
CN¥1.60 Billion ≈ $234.43 Million |
+1.49pp |
| 2014-12-31 | 20.69% | CN¥320.00 Million ≈ $46.83 Million |
CN¥1.55 Billion ≈ $226.35 Million |
+20.68pp |
| 2009-12-31 | 0.01% | CN¥74.94K ≈ $10.97K |
CN¥1.30 Billion ≈ $189.66 Million |
+0.00pp |
| 2008-12-31 | 0.00% | CN¥44.58K ≈ $6.52K |
CN¥1.16 Billion ≈ $169.60 Million |
0.00pp |
| 2006-12-31 | 0.00% | CN¥46.00K ≈ $6.73K |
CN¥1.05 Billion ≈ $153.91 Million |
-0.16pp |
| 2005-12-31 | 0.17% | CN¥1.77 Million ≈ $258.68K |
CN¥1.06 Billion ≈ $155.25 Million |
-0.04pp |
| 2004-12-31 | 0.21% | CN¥1.90 Million ≈ $277.46K |
CN¥924.49 Million ≈ $135.28 Million |
+0.14pp |
| 2003-12-31 | 0.07% | CN¥362.79K ≈ $53.09K |
CN¥532.62 Million ≈ $77.94 Million |
+0.05pp |
| 2002-12-31 | 0.02% | CN¥103.62K ≈ $15.16K |
CN¥453.85 Million ≈ $66.41 Million |
-0.01pp |
| 2001-12-31 | 0.03% | CN¥133.86K ≈ $19.59K |
CN¥398.42 Million ≈ $58.30 Million |
-- |
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells traditional Chinese medicines and paediatric products in China. It provides over-the-counter, medical, and general health products in the form of capsules, granules, and gels under the Jianmin, Longmu, and Yekaitai brands. The company was founded in 1637 and is based in Wuhan, China.